VEGF can protect against blood brain barrier dysfunction, dendritic spine loss and spatial memory impairment in an experimental model of diabetes

Neurobiology of Disease

Volumn 78, Issue , 2015, Pages 1-11

  Taylor, Stephanie L ^a   Trudeau, Dustin ^a   Arnold, Brendan ^a   Wang, Joshua ^a   Gerrow, Kim ^a   Summerfeldt, Kieran ^a   Holmes, Andrew ^a   Zamani, Akram ^a   Brocardo, Patricia S ^a   Brown, Craig E ^a,b  

^a UNIVERSITY OF VICTORIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Blood brain barrier; Dendritic spines; Diabetes; Hippocampus; Learning and memory; Vascular endothelial growth factor

Indexed keywords

PROTEIN KINASE B; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER DYSFUNCTION; CELL LOSS; COGNITIVE DEFECT; CONTROLLED STUDY; DENDRITIC SPINE; DENTATE GYRUS; DOWNSTREAM PROCESSING; HEMATOLOGIC DISEASE; HIPPOCAMPUS; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MEMORY DISORDER; MORRIS WATER MAZE TEST; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; BLOOD BRAIN BARRIER; C57BL MOUSE; DIABETES MELLITUS, TYPE 1; DISEASE MODEL; DRUG EFFECTS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; PSYCHOLOGY; SPATIAL MEMORY; VASCULARIZATION;

ANIMALS; BLOOD-BRAIN BARRIER; DENDRITIC SPINES; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; INFUSIONS, INTRAVENTRICULAR; MALE; MICE; MICE, INBRED C57BL; SPATIAL MEMORY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84926374530     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.03.022     Document Type: Article

References (79)

1. Antenor-Dorsey J.A., et al. White matter microstructural integrity in youth with type 1 diabetes. Diabetes 2013, 62:581-589.
2. Argandona E.G., et al. Effect of intracortical vascular endothelial growth factor infusion and blockade during the critical period in the rat visual cortex. Brain Res. 2012, 1473:141-154.
3. Bardal S., et al. Chronic treatment with vascular endothelial growth factor preserves agonist-evoked vascular responses in the streptozotocin-induced diabetic rat. Diabetologia 2006, 49:811-818.
4. Biessels G.J., Gispen W.H. The impact of diabetes on cognition: what can be learned from rodent models?. Neurobiol. Aging 2005, 26(Suppl. 1):36-41.
5. Biessels G.J., et al. Cerebral function in diabetes mellitus. Diabetologia 1994, 37:643-650.
6. Biessels G.J., et al. Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats. Diabetes 1996, 45:1259-1266.
7. Biessels G.J., et al. Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment. Brain Res. 1998, 800:125-135.
8. Biessels G.J., et al. Neurophysiological changes in the central and peripheral nervous system of streptozotocin-diabetic rats. Course of development and effects of insulin treatment. Brain 1999, 122(Pt 4):757-768.
9. Biessels G.J., et al. Cognition and diabetes: a lifespan perspective. Lancet Neurol. 2008, 7:184-190.
10. Brands A.M., et al. The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care 2005, 28:726-735.
11. Brismar T., et al. Predictors of cognitive impairment in type 1 diabetes. Psychoneuroendocrinology 2007, 32:1041-1051.
12. Caldwell R.B., et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr. Drug Targets 2005, 6:511-524.
13. Cao L., et al. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat. Genet. 2004, 36:827-835.
14. Carmeliet P., Storkebaum E. Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin. Cell Dev. Biol. 2002, 13:39-53.
15. Clark R.E., et al. Intact performance on feature-ambiguous discriminations in rats with lesions of the perirhinal cortex. Neuron 2011, 70:132-140.
16. den Heijer T., et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 2003, 46:1604-1610.
17. Dietrich W.D., et al. Moderate hyperglycemia worsens acute blood-brain barrier injury after forebrain ischemia in rats. Stroke 1993, 24:111-116.
18. Feng G., et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 2000, 28:41-51.
19. Franc D.T., et al. High connectivity between reduced cortical thickness and disrupted white matter tracts in long-standing type 1 diabetes. Diabetes 2011, 60:315-319.
20. Francis G.J., et al. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 2008, 131:3311-3334.
21. Gagne J., et al. Binding properties of glutamate receptors in streptozotocin-induced diabetes in rats. Diabetes 1997, 46:841-846.
22. Gaudieri P.A., et al. Cognitive function in children with type 1 diabetes: a meta-analysis. Diabetes Care 2008, 31:1892-1897.
23. Gold S.M., et al. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia 2007, 50:711-719.
24. Haigh J.J., et al. Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev. Biol. 2003, 262:225-241.
25. Harik S.I., LaManna J.C. Vascular perfusion and blood-brain glucose transport in acute and chronic hyperglycemia. J. Neurochem. 1988, 51:1924-1929.
26. Hawkins B.T., et al. Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia 2007, 50:202-211.
27. Huber J.D. Diabetes, cognitive function, and the blood-brain barrier. Curr. Pharm. Des. 2008, 14:1594-1600.
28. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol. 2010, 120:287-296.
29. Jakobsen J., et al. Regional brain glucose metabolism and blood flow in streptozocin-induced diabetic rats. Diabetes 1990, 39:437-440.
30. Jin K.L., et al. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:10242-10247.
31. Kelly-Cobbs A., et al. Pressure-independent cerebrovascular remodelling and changes in myogenic reactivity in diabetic Goto-Kakizaki rat in response to glycaemic control. Acta Physiol (Oxf.) 2011, 203:245-251.
32. Kennedy J.M., Zochodne D.W. Experimental diabetic neuropathy with spontaneous recovery: is there irreparable damage?. Diabetes 2005, 54:830-837.
33. Kerti L., et al. Higher glucose levels associated with lower memory and reduced hippocampal microstructure. Neurology 2013, 81:1746-1752.
34. King G.L., et al. Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J. Clin. Invest. 1985, 75:1028-1036.
35. Knudsen G.M., et al. Regional density of perfused capillaries and cerebral blood flow in untreated short-term and long-term streptozotocin diabetes. J. Cereb. Blood Flow Metab. 1991, 11:361-365.
36. Lee S., et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007, 130:691-703.
37. Lee C.C., et al. Insulin promotes dendritic spine and synapse formation by the PI3K/Akt/mTOR and Rac1 signaling pathways. Neuropharmacology 2011, 61:867-879.
38. Li W., et al. Adaptive cerebral neovascularization in a model of type 2 diabetes: relevance to focal cerebral ischemia. Diabetes 2010, 59:228-235.
39. Liu J., et al. Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells. Angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1. J. Biol. Chem. 1999, 274:15781-15785.
40. Ma Y., et al. Effects of vascular endothelial growth factor in ischemic stroke. J. Neurosci. Res. 2012, 90(10):1873-1882.
41. Manschot S.M., et al. Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-diabetic rats. Brain Res. 2003, 966:274-282.
42. Manschot S.M., et al. Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 2006, 55:1106-1113.
43. Martinez-Tellez R., et al. Alteration in dendritic morphology of cortical neurons in rats with diabetes mellitus induced by streptozotocin. Brain Res. 2005, 1048:108-115.
44. Mendonca M.C., et al. Expression of VEGF and Flk-1 and Flt-1 receptors during blood-brain barrier (BBB) impairment following Phoneutria nigriventer spider venom exposure. Toxins (Basel) 2013, 5:2572-2588.
45. Morris R.G., et al. Place navigation impaired in rats with hippocampal lesions. Nature 1982, 297:681-683.
46. Mumby D.G., Pinel J.P. Rhinal cortex lesions and object recognition in rats. Behav. Neurosci. 1994, 108:11-18.
47. Newton S.S., et al. Vascular growth factors in neuropsychiatry. Cell. Mol. Life Sci. 2013, 70:1739-1752.
48. Ortuzar N., et al. VEGF reverts the cognitive impairment induced by a focal traumatic brain injury during the development of rats raised under environmental enrichment. Behav. Brain Res. 2013, 246:36-46.
49. Poe G.R., et al. Partial hippocampal inactivation: effects on spatial memory performance in aged and young rats. Behav. Neurosci. 2000, 114:940-949.
50. Popovic M., et al. Learning and memory in streptozotocin-induced diabetic rats in a novel spatial/object discrimination task. Behav. Brain Res. 2001, 122:201-207.
51. Prakash R., et al. Enhanced cerebral but not peripheral angiogenesis in the Goto-Kakizaki model of type 2 diabetes involves VEGF and peroxynitrite signaling. Diabetes 2012, 61:1533-1542.
52. Prakash R., et al. Cerebral neovascularization and remodeling patterns in two different models of type 2 diabetes. PLoS ONE 2013, 8:e56264.
53. Quaegebeur A., et al. The neurovascular link in health and disease: molecular mechanisms and therapeutic implications. Neuron 2011, 71:406-424.
54. Reeson P., et al. Delayed inhibition of VEGF signaling after stroke attenuates blood brain barrier breakdown and improves functional recovery in a co-morbidity dependent manner. J. Neurosci. 2015, 35:5128-5143.
55. Ruiz de Almodovar C., et al. Role and therapeutic potential of VEGF in the nervous system. Physiol. Rev. 2009, 89:607-648.
56. Seaquist E.R. The final frontier: how does diabetes affect the brain?. Diabetes 2010, 59:4-5.
57. Shehata G., Eltayeb A. Cognitive function and event-related potentials in children with type 1 diabetes mellitus. J. Child Neurol. 2010, 25:469-474.
58. Storkebaum E., et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci. 2005, 8:85-92.
59. Stranahan A.M., Mattson M.P. Impact of energy intake and expenditure on neuronal plasticity. Neuromol. Med. 2008, 10:209-218.
60. Stranahan A.M., et al. Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat. Neurosci. 2008, 11:309-317.
61. Stranahan A.M., et al. Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 2008, 18:1085-1088.
62. Su E.N., et al. An experimental study of VEGF induced changes in vasoactivity in pig retinal arterioles and the influence of an anti-VEGF agent. BMC Ophthalmol. 2012, 12:10.
63. Sun Y., et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J. Clin. Invest. 2003, 111:1843-1851.
64. Sutherland R.J., et al. A behavioural analysis of spatial localization following electrolytic, kainate- or colchicine-induced damage to the hippocampal formation in the rat. Behav. Brain Res. 1983, 7:133-153.
65. Sweetnam D., et al. Diabetes impairs cortical plasticity and functional recovery following ischemic stroke. J. Neurosci. 2012, 32:5132-5143.
66. Tennant K.A., Brown C.E. Diabetes augments in vivo microvascular blood flow dynamics after stroke. J. Neurosci. 2013, 33:19194-19204.
67. Tennant K.A., Jones T.A. Sensorimotor behavioral effects of endothelin-1 induced small cortical infarcts in C57BL/6 mice. J. Neurosci. Methods 2009, 181:18-26.
68. Toth C., et al. Diabetes, leukoencephalopathy and rage. Neurobiol. Dis. 2006, 23:445-461.
69. Vinik A., Flemmer M. Diabetes and macrovascular disease. J. Diabet. Complications 2002, 16:235-245.
70. Warner-Schmidt J.L., Duman R.S. VEGF as a potential target for therapeutic intervention in depression. Curr. Opin. Pharmacol. 2008, 8:14-19.
71. Warren C.M., et al. A ligand-independent VEGFR2 signaling pathway limits angiogenic responses in diabetes. Sci. Signal. 2014, 7:ra1.
72. Winters B.D., Bussey T.J. Transient inactivation of perirhinal cortex disrupts encoding, retrieval, and consolidation of object recognition memory. J. Neurosci. 2005, 25:52-61.
73. Won S.J., et al. Hyperglycemia promotes tissue plasminogen activator-induced hemorrhage by increasing superoxide production. Ann. Neurol. 2011, 70:583-590.
74. Wu W., et al. The brain in the age of old: the hippocampal formation is targeted differentially by diseases of late life. Ann. Neurol. 2008, 64:698-706.
75. Ye X., et al. Niaspan enhances vascular remodeling after stroke in type 1 diabetic rats. Exp. Neurol. 2011, 232:299-308.
76. Zhang Z.G., Chopp M. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol. 2009, 8:491-500.
77. Zhang Z.G., et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J. Clin. Invest. 2000, 106:829-838.
78. Zhao Q., et al. Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain. BMC Complement. Altern. Med. 2012, 12:188.
79. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57:178-201.